4/A: Actuate Therapeutics Insider Amends Form 4 to Correct Price Reporting After IPO

An amended SEC Form 4 filing reveals a correction to the price reported in a previous filing related to warrant exercises following Actuate Therapeutics' IPO, with no new transactions reported.

Summary

• This is an amendment to a Form 4 filing related to Actuate Therapeutics.
• The original filing, dated August 14, 2024, contained an incorrect price in Table I.
• The amendment corrects the price but does not report any new transactions.
• The filing concerns the exercise of warrants held by various entities affiliated with Bios Equity Partners in connection with Actuate Therapeutics' IPO on August 12, 2024.
• The warrants were exercised on a cashless basis, resulting in the withholding of shares to cover the exercise price.
• Aaron G.L. Fletcher, a director and 10% owner, is the reporting person, along with several Bios Equity Partners entities.
• The corrected filing reflects the transactions related to the automatic exercise of warrants to purchase common stock at $5.27 per share.
• The shares are held indirectly by Bios Fund II, LP, Bios Fund II QP, LP, and Bios Fund II NT, LP.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Key Dates